GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » Net Cash per Share

Chordate Medical Holding AB (OSTO:CMH) Net Cash per Share : kr0.01 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Chordate Medical Holding AB's Net Cash per Share for the quarter that ended in Dec. 2023 was kr0.01.

The historical rank and industry rank for Chordate Medical Holding AB's Net Cash per Share or its related term are showing as below:

OSTO:CMH' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6   Med: 12.18   Max: 12.18
Current: 6.4

During the past 9 years, the highest Price-to-Net-Cash Ratio of Chordate Medical Holding AB was 12.18. The lowest was 6.00. And the median was 12.18.

OSTO:CMH's Price-to-Net-Cash is ranked better than
53.67% of 341 companies
in the Medical Devices & Instruments industry
Industry Median: 7.11 vs OSTO:CMH: 6.40

Chordate Medical Holding AB Net Cash per Share Historical Data

The historical data trend for Chordate Medical Holding AB's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordate Medical Holding AB Net Cash per Share Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only -0.09 0.09 0.15 -0.02 0.01

Chordate Medical Holding AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 0.07 0.05 0.04 0.01

Competitive Comparison of Chordate Medical Holding AB's Net Cash per Share

For the Medical Devices subindustry, Chordate Medical Holding AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordate Medical Holding AB's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's Price-to-Net-Cash falls into.



Chordate Medical Holding AB Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Chordate Medical Holding AB's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(8.455-6.869-0)/306.025
=0.01

Chordate Medical Holding AB's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(8.455-6.869-0)/306.025
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chordate Medical Holding AB  (OSTO:CMH) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Chordate Medical Holding AB Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Chordate Medical Holding AB's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Chordate Medical Holding AB (OSTO:CMH) Business Description

Traded in Other Exchanges
Address
c/o Regus, Kistagangen 20B, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines